Electronic Consent Becomes Reality in England
The U.K. National Health Service (NHS) has granted approval for what is thought to be the first use of electronic informed consent in England.
The U.K. National Health Service (NHS) has granted approval for what is thought to be the first use of electronic informed consent in England. The equipment for the trial will be provided by Mytrus, a California-based company.
The Health Research Authority (HRA), a division of the NHS, granted the approval to use e-Consent in a trial by a top-ten global pharmaceutical company, according to Mytrus. HRA, which oversees both research ethics committees and research innovation, was established to promote and protect the interests of patients participating in research. The plan is to use the results from the study to produce a paper that could serve as guidance for other national health authorities looking at ways to speed up the start of trials while assuring patients are at the center of decision-making.
Mytrus’ Enroll platform uses iPads to offer trial subjects an introductory overview and videos to reinforce key information. Potential trial subjects read the informed consent document, answer a set of questions to assess comprehension, and are prompted to review information they understand less well to help them make better, more informed decisions.
Research site staff can track patient metrics to determine where patients need counseling and dedicate time for each potential study participant to discuss the study with site staff before agreeing to give their consent. E-consent not only improves the patient experience, it also streamlines and speeds the costly enrollment process, according to the vendor.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
